13.955  0.575 (4.3%)		12-05 10:04
Open: 13.5 High: 14.4898 Volume: 55,065		Pre. Close: 13.38 Low: 13.5 Market Cap: 23(M)

Short term
Mid term
Targets	6-month :	18.96	1-year :	22.14
Resists	First :	16.23	Second :	18.96
Pivot price	9.56
Supports	First :	9.64	Second :	5.57
MAs	MA(5) :	12	MA(20) :	9.03
	MA(100) :	8.08	MA(250) :	0
MACD	MACD :	1.4	Signal :	0.8
%K %D	K(14,3) :	80.2	D(3) :	69.8
RSI	RSI(14): 69.7
52-week	High :	16.23	Low :	2.85

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ KZIA ] has closed below upper band by 7.3%. Bollinger Bands are 323% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	16.25 - 16.32	16.32 - 16.38
Low:	12.7 - 12.76	12.76 - 12.83
Close:	13.28 - 13.37	13.37 - 13.47

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Tue, 02 Dec 2025
Kazia Therapeutics Secures $50 Million in Private Placement to Advance Cancer Drug Development - TipRanks

Tue, 02 Dec 2025
Kazia Therapeutics raises $50 million in private placement By Investing.com - Investing.com Nigeria

Tue, 02 Dec 2025
What's Going On With Cancer Firm Kazia Therapeutics - Benzinga

Tue, 02 Dec 2025
Kazia Therapeutics (KZIA) Secures $50M Through Private Placement - GuruFocus

Tue, 02 Dec 2025
Kazia Therapeutics announces pricing of $50.0 million private placement of equity securities - marketscreener.com

Tue, 02 Dec 2025
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	843 (M)
Held by Insiders	8.9 (%)
Held by Institutions	11.1 (%)
Shares Short	12 (K)
Shares Short P.Month	17 (K)

EPS	-12.36
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-5.14
Profit Margin	0 %
Operating Margin	-268.4 %
Return on Assets (ttm)	-64.3 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	-27.3 %
Gross Profit (p.s.)	1.09
Sales Per Share	1.09
EBITDA (p.s.)	-7.96
Qtrly Earnings Growth	0 %
Operating Cash Flow	-13 (M)
Levered Free Cash Flow	-15 (M)

PE Ratio	-1.15
PEG Ratio	0
Price to Book value	-2.77
Price to Sales	12.93
Price to Cash Flow	-1.79

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.